Lynda Charters



EURETINA 2022: LIGHT study offers first analysis of gene therapy for RPE65 inherited retinal dystrophies

At the 22nd EURETINA World Congress in Hamburg, Germany,Isabelle Audo, MD, reported that voretigene neparvovec used to treat patients with a RPE65-related inherited retinal dystrophy, showed good safety and efficacy at the 1-year time point of the LIGHT Study.

Controlling glaucoma: Eye drop therapy reaches posterior ocular tissues

A novel eye drop under development may provide neuroprotection to the retinal ganglion cells.

Study finds subretinal implant for advanced dry AMD is safe, well-tolerated

In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Amir Kashani, MD, PhD, discussed results that show the implant procedure is feasible on an outpatient basis and has a good safety and efficacy profile.